Notes

A news scan found the headline of a job report. The report is about a fund called Catalyst Research, which has a size of 0 and compact receipts. The origins of the report are in the PRE91108 archive, and it was last updated on 2026-09-30T15:16:28.653473+00:00. The report includes a list of panels with different information, including SEC filings for HITI and BFRI, and news about Dave & Buster's and Egetis Therapeutics. A SEC filing, or Securities and Exchange Commission filing, is a document that a company submits to the SEC. The report also mentions a SHA, or Secure Hash Algorithm, which is a way to identify and verify the integrity of a piece of data. The panels include information about the companies, such as their SEC filings and news releases. For example, BFRI had an ITC, or International Trade Commission, case about photodynamic therapy systems. The report also mentions a UTC, or Coordinated Universal Time, which is a way to express time in a standardized way. The report includes 11 panels with different information, and the originals should be read before taking any action.

A news scan found the headline of a job report. The fund is called Catalyst Research and its size is 0. It has compact receipts and its origins are in the PRE91108 archive. The report was made on 2026-09-30T07:01:37.101260+00:00. The report includes a list of panels with different information. Panel 0 has a preview of the fund and its size. Panel 1 has a link to a SEC filing for HITI on 2026-09-28. Panel 2 has a link to a SEC filing for BFRI on 2026-09-14. Panel 3 has a preview of a report from Dave & Buster's on September 14, 2026. Panel 4 has a preview of chosen UTC reviews. Panel 5 has a preview of new information about CAN and PLAY. Panel 6 has a preview of improved organic cash and clinical evidence. Panel 7 has information about EGTX, including a count of 48 and a latest link. Panel 8 has a preview of chosen reviews for EGTX. Panel 9 has a link to an ITC page for BFRI. Panel 10 has a link to a federal register page about BFRI. The report ends with a note to read the originals before taking action.

The fund is called Catalyst Research and its size is 0. It has compact receipts and its origins are in the PRE91108 archive. The last update was on 2026-09-29 at 23:01:12.385953+00:00. The system checked various sources, including SEC filings for HITI on 2026-09-28 and BFRI on 2026-09-14. It also looked at news about Dave & Buster's second quarter 2026 report on September 14, 2026. Additionally, the system reviewed chosen UTC reviews and data from TSM on September 10. There were updates on CAN on September 8 and PLAY on September 15. All branches showed improved organic cash and credible clinical evidence, leading to a record prospectus. The system also checked the EGTX MFN count, which was 48, and reviewed conferences on September 11 and 16. Furthermore, the system looked at ITC information for BFRI and a lifted suspension on September 1. The system has 11 panels with raw sha d47074220397b707c3b90cd00a8ead0e9adfee046a667f2d5fa284edc658caf4.

The fund is called Catalyst Research and it has a size of 0. It is a compact version of receipts and its origins are in the PRE91108 archive. The information was last updated on 2026-09-29 at 15:01:12.652024 UTC. There are 11 panels of information, including updates on HITI SEC from 2026-09-28, BFRI SEC from 2026-09-14, and PLAY from September 14, 2026. Other updates include information on TSM, DATA.L, CAN, and EGTX. The fund also includes information on BFRI's ITC and a lifted suspension on September 1, 2026. The original panels and previews are available for review before taking any action.

A news scan found the headline 'fund=catalyst research only; size=0; compact receipts; origins in PRE91108 archive; 2026-09-29T06:46:14.882167+00:00'. This is a list of 11 panels with their respective previews: 1. 'HITI SEC 2026-09-28 https://www.sec.gov/Archives/edgar/data/1847409/0001279569260', 2. 'BFRI SEC 2026-09-14 https://www.sec.gov/Archives/edgar/data/1858685/0001493152260', 3. 'PLAY Mon, 14 Sep 2026 16:05:00 -0400 Dave & Buster’s Reports Second Quarter 2026 ', 4. 'STATIC chosen UTC reviews,not guaranteed release/delivery: TSM Sep10 06; DATA.L S', 5. 'NEW: CAN Sep8 12:30 after beforeopen results/08ETcall; PLAY Sep15 12:30 after Sep', 6. 'All branches: improved organic cash/credibleclinical evidence -> record prospecti', 7. 'EGTX MFN count=48 hash=a8c5a7657b07 latest=https://mfn.se/a/egetis-therapeutics/e', 8. 'EGTX chosen reviews Sep11 13:50UTC/Sep16 19:40UTC conferences; Sep25 12:30 before', 9. 'BFRI ITC https://www.usitc.gov/photodynamic_therapy_systems_components_thereof sh', 10. 'BFRI Sep1 ITC lifted028suspension: https://public-inspection.federalregister.gov/'. The job has completed with 11 panels and their respective rawsha and previews.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-28T22:45:59.496127+00:00. A news scan found the following headlines and data lines: a panel about HITI SEC on 2026-09-28, a panel about BFRI SEC on 2026-09-14, a panel about Dave & Buster's second quarter 2026 report on September 14, 2026, a panel about chosen UTC reviews, a panel about CAN and PLAY on September 8 and 15, a panel about improved organic cash and credible clinical evidence, a panel about EGTX with a count of 48 and a hash of a8c5a7657b07, a panel about EGTX chosen reviews on September 11 and 16, a panel about BFRI ITC, and a panel about BFRI ITC lifting a suspension on September 1. These are previews of the originals, which should be read before taking any action.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-28 at 14:31:10. There are 11 panels of information. The panels contain various pieces of data, including SEC filings for HITI and BFRI, a report from Dave & Buster's, and information about TSM, DATA.L, CAN, and EGTX. One piece of jargon used is SEC, which stands for Securities and Exchange Commission. Another piece of jargon used is ITC, which stands for International Trade Commission. The information also includes links to websites, such as https://www.sec.gov/ and https://www.usitc.gov/. The data includes hashes, such as feaa31c826265772 and 03e9cdc40c1fe84e, and timestamps, such as 2026-09-28T14:31:05.459172+00:00. The panels also mention conferences and before-open results.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 28, 2026, at 12:31:04 UTC. The fund is tracking the following stocks: IONS, MIRM, GIS, EAT, and CAG. Recent SEC filings include: IONS on September 23, MIRM on September 28, GIS on September 23, and EAT on September 17. A news scan found the headline 'Mirum Pharma's Brelovitug Meets Phase 3 Primary Endpoint In AZURE-1 Study For Chronic Hepatitis Delta Virus' on September 28. GIS had a conference on September 8, and will have earnings on September 23, with a Q&A session at 13 UTC. The fund's baseline for GIS is an EPS of 3.00-3.20 for FY27, with organic growth of -1.5 to +0.5%, and savings of 750m. EAT had an investor day on September 17, and will have an earnings call on October 28. The fund's strategy for EAT is to record and independently validate stronger organic cash, and to reverify weaker or absent cash. The fund is not set to automatically trade, and all dates are for review only, not for first news. The fund's current status is research only, with no orders, as of the last update.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 28, 2026, at 08:31:02 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, EAT, and CAG. A news scan found the following SEC filings: IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. On September 25, the FDA approved Atebrioz for Fibrodysplasia Ossificans Progressiva in adults and pediatric patients. GIS had a conference on September 8, and will have earnings and a Q&A session on September 23. The fund will review GIS's organic cash and guide, and verify its cash if it is weaker or absent. The baseline for GIS is an EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750m. EAT had an investor day on September 17, and will have an earnings call on October 28. The fund will review EAT's organic cash and verify its cash if it is weaker or absent. The fund is monitoring four SEC filings, one discovery, two GIS events, and two EAT events, and will verify full pipelines and early news.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size, as of September 28, 2026, at 00:15:58 UTC. The fund manager reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. On September 25, the FDA approved Atebrioz for a specific medical condition. GIS had a conference on September 8, which has already passed, and will have earnings and a Q&A session on September 23. The fund manager will review GIS's performance, specifically its organic cash flow, to decide whether to record and validate or reverify its cash flow. The baseline for GIS's fiscal year 2027 is an EPS of 3.00-3.20, with organic growth between -1.5% and +0.5%, and savings of 750 million. EAT had an investor day on September 17 and will have an earnings call on October 28. The fund manager will review EAT's performance, specifically its organic cash flow, to decide whether to record and validate or reverify its cash flow. The fund is currently in research mode only, with no orders, and will verify full pipelines and early news for IONS, MIRM, GIS, EAT, and one discovery.

The Catalyst fund is currently in research mode only for the stocks IONS, MIRM, GIS, and EAT, with a size of 0. The fund's status was updated on September 27, 2026, at 20:15:57 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on September 25. The GIS company had a conference on September 8, which has already passed, and is scheduled to release its earnings on September 23. The fund manager will review the earnings report at 13:00 UTC and will verify the cash flow and guidance. If the cash flow is strong, the fund manager will record and validate the results, but if it is weak or absent, the fund manager will reverify the cash flow. The fund manager has set a baseline for the stock's performance, with an expected EPS of 3.00-3.20 and organic growth of -1.5 to +0.5%. The EAT company had an investor day on September 17 and is scheduled to release its earnings on October 28. The fund manager will review the earnings report at 16:30 UTC and will verify the cash flow and guidance. If the cash flow is strong, the fund manager will record and validate the results, but if it is weak or absent, the fund manager will reverify the cash flow. The fund manager has not set any automatic trades and will verify the full pipelines and early news for all stocks.

The fund, called Catalyst, is researching the stocks IONS, MIRM, GIS, EAT, and CAG, but has not invested in them yet. The research started on September 27, 2026, at 16:01:07 UTC. The fund manager has been looking at the SEC filings of these companies, including IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. There was also a discovery on September 25 about the FDA approving a new treatment. The GIS company had a conference on September 8, and the fund manager is waiting for the replay. The STATIC company had earnings on September 23, and the fund manager is checking the Q&A session. The fund manager is looking at the organic cash flow of GIS and EAT, and will record and validate if it is strong, or reverify if it is weak. The fund manager has set a baseline for the EPS of GIS and will check if it meets the expectations. The EAT company had an investor day on September 17, and the fund manager is reviewing it. The fund manager is also waiting for the earnings call of EAT on October 28. The fund manager has set rules for trading, but will not make any automatic trades. The fund manager will verify the full pipelines and early news before making any decisions.

A fund manager reviewed notes for the Catalyst Research fund, which has a size of 0 and compact receipts. The origins of the notes are in the PRE91108 archive, and the review was done on 2026-09-27T14:01:14.145791+00:00. The manager looked at 11 panels of information, including SEC filings for HITI and BFRI, and news about Dave & Buster's and Egetis Therapeutics. The manager also reviewed information about photodynamic therapy systems and a lifted suspension by the ITC. The panels included previews of the information, but the manager notes that the originals should be read before taking any action.

The fund is called Catalyst and it is for research on IONS, MIRM, and GIS only, with a size of 0. The current time is 2026-09-27T12:01:09.157833+00:00 UTC. There are SEC filings for IONS on 2026-09-23, MIRM on 2026-09-08, GIS on 2026-09-23, and EAT on 2026-09-17. On 2026-09-25, the FDA approved Atebrioz for Fibrodysplasia Ossificans Progressiva in adults and pediatric patients. GIS had a conference on September 8 at 19 UTC, which has already passed. On September 23, GIS released its morning earnings, with a Q&A session at 13 UTC. The first release time is unknown. If GIS has stronger organic cash and guidance, it will be recorded and validated, but if it is weaker or absent, the cash will be reverified. There will be no automatic entry, and the dates are for reviews, not first news. The baseline for July 1 FY27 is an EPS of 3.00-3.20, with organic growth of -1.5 to +0.5% and savings of 750m. EAT had an investor day on August 31, with a review on September 17 at 16:30 UTC. EAT also has an earnings call scheduled for October 28, with a review at 16:30 UTC. If EAT has stronger organic cash, it will be recorded and validated, but if it is weaker or absent, the cash will be reverified. The fund has 4 SEC filings, 1 discovery, 2 GIS reviews, and 2 EAT reviews, and the full pipelines and early news need to be verified. The fund is for research only and no orders will be placed.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size, as of September 27, 2026, at 08:01:09 UTC. The fund manager reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on September 25. GIS had a conference on September 8, which has already passed, and will have earnings on September 23, with a Q&A session at 13 UTC. The fund manager will review GIS's stronger organic cash flow and guide, but will not automatically enter a trade. The baseline for GIS is a fiscal year 2027 EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750 million. EAT had an investor day on September 17 and will have an earnings call on October 28. The fund manager will review EAT's stronger organic cash flow, but will not automatically trade. The fund manager will verify full pipelines and early news for IONS, MIRM, GIS, EAT, and one discovery, with two reviews for GIS and two for EAT. The fund is for research only, with no orders.

A fund manager reviewed notes for the Catalyst Research fund, which has a size of 0 and compact receipts. The origins of the notes are in the PRE91108 archive, and the review took place on 2026-09-27T06:01:15.300204+00:00. The manager looked at various panels, including a news scan that found the headline 'HITI SEC 2026-09-23' with a link to https://www.sec.gov/Archives/edgar/data/1847409/0001279569260, and another panel with a link to a BFRI SEC filing from 2026-09-14 at https://www.sec.gov/Archives/edgar/data/1858685/0001493152260. Other panels mentioned Dave & Buster's second quarter 2026 report, a chosen review of TSM on September 10, and a review of EGTX on September 11 and 16. The manager also looked at a panel about BFRI's ITC case at https://www.usitc.gov/photodynamic_therapy_systems_components_thereof and a panel about the lifting of a suspension on September 1, as reported at https://public-inspection.federalregister.gov/. The review consisted of 11 panels, with a total of 17118c87e20f1cf650b4dacdb1fc5e3cb53b556d6149a6f15b1c6b6963378efc raw sha.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size, as of September 27, 2026, at 03:45:59 UTC. The fund manager reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on September 25. GIS had a conference on September 8, which has already passed, and will have earnings on September 23, with a Q&A session at 13:00 UTC. The fund manager will review GIS's organic cash and guide, and will not make automatic entries. The baseline for GIS is a fiscal year 2027 EPS of 3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of 750 million. EAT had an investor day on September 17, and will have an earnings call on October 28, with a review at 16:30 UTC. The fund manager will review EAT's organic cash and will not make automatic trades. The fund is for research only, with no orders.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active orders. As of September 26, 2026, at 23:31:01 UTC, the fund size is 0. Recent SEC filings include IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on September 25. GIS had a conference on September 8, and STATIC had morning earnings on September 23. The fund uses a baseline of July 1 FY27 EPS 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750m. EAT had an investor day on August 31 and an earnings call date set for October 28. The fund will review EAT on October 28 at 16:30 UTC. The fund has a frozen paper window and does not automatically enter trades. It also verifies full pipelines and early news. The fund is currently in research mode only, with no orders.

The fund is called Catalyst Research and its size is 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-26 at 22:01:11.945068+00:00. There are 11 panels of information. The first panel has 70 characters and a sha, or secure hash algorithm, of 3bdb52a394545278. The second panel has 101 characters and a sha of 500ba2c662d2e8b2, and it mentions HITI SEC on 2026-09-23. The third panel has 98 characters and a sha of a0b1c61a5d55ddaa, and it mentions BFRI SEC on 2026-09-14. The fourth panel has 216 characters and a sha of d8aa654ed382a608, and it mentions Dave & Buster's Reports on September 14, 2026. The fifth panel has 246 characters and a sha of c6b13eb6046204c9, and it mentions TSM and DATA.L. The sixth panel has 260 characters and a sha of 1a27b01a67d941ba, and it mentions CAN and PLAY. The seventh panel has 353 characters and a sha of 6c9b3b8c9ef9591b, and it mentions organic cash and clinical evidence. The eighth panel has 160 characters and a sha of cb0697f278f531de, and it mentions EGTX and MFN. The ninth panel has 206 characters and a sha of 07d3a925356adce6, and it mentions EGTX conferences. The tenth panel has 99 characters and a sha of e69eecebaceb3942, and it mentions BFRI ITC. The eleventh panel has 341 characters and a sha of 54d249f97f35ce8c, and it mentions BFRI and ITC suspension lifted on September 1.

The fund, called Catalyst, is for research on IONS, MIRM, GIS, and EAT, plus CAG, with a size of 0, as of September 26, 2026, at 19:16:04 UTC. The fund manager reviewed SEC filings for IONS on September 23, MIRM on September 8, GIS on September 23, and EAT on September 17. A discovery was made on September 25 that the FDA approved Atebrioz for a specific medical condition. GIS had a conference on September 8, which is already past, and the manager will check the replay. On September 23, GIS released its morning earnings, and the manager will review the Q&A session. The manager will verify GIS's organic cash and guide, and if it is stronger, will record and validate, but if it is weaker or absent, will reverify the cash. There will be no automatic entry, and the dates are for review, not first news. The baseline for GIS is an EPS of 3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of 750 million. The manager also reviewed EAT's investor day on September 17 and its earnings call date on October 28. For EAT, if the organic cash is stronger, the manager will record and independently validate, but if it is weaker or absent, will reverify the cash. The manager will verify the full pipelines and early news for all four companies, and notes that the fund is for research only, with no orders.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no active trades. The fund size is 0 and the current time is 2026-09-26T15:16:04.831193+00:00. Recent SEC filings include IONS on 2026-09-23, MIRM on 2026-09-08, GIS on 2026-09-23, and EAT on 2026-09-17. A news scan found the headline 'FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients' on 2026-09-25. GIS had a conference on September 8, which has already passed. GIS will release earnings on the morning of September 23, with a Q&A session at 13UTC. The baseline for GIS is an EPS of 3.00-3.20 for FY27, with organic growth of -1.5 to +0.5% and savings of 750m. EAT had an investor day on September 17 and will have an earnings call on October 28. The fund will verify full pipelines and early news for GIS and EAT. The fund is currently in research mode only, with no orders.

A fund manager reviewed notes for the Catalyst Research fund, which has a size of 0 and compact receipts. The origins of the fund are in the PRE91108 archive, and the review was done on 2026-09-26T13:46:08.133945+00:00. The manager looked at various panels, including one about HITI SEC from 2026-09-23, another about BFRI SEC from 2026-09-14, and a news article about Dave & Buster's second quarter 2026 report from September 14, 2026. The manager also reviewed panels about TSM, DATA.L, CAN, PLAY, and EGTX, including a panel about EGTX's MFN count and hash. Additionally, the manager looked at panels about BFRI's ITC and a lifted suspension on September 1, 2026. The review included 11 panels with various previews and hashes, and the manager noted that the previews are not guaranteed to be up-to-date or accurate, and that the originals should be read before taking any action.